PHYSIOLOGICAL INHIBITORS OF COAGULATION IN FULMINANT HEPATIC-FAILURE

被引:13
|
作者
LANGLEY, PG
WILLIAMS, R
机构
[1] UNIV LONDON KINGS COLL HOSP,INST LIVER STUDIES,DENMARK HILL,LONDON SE5 9RS,ENGLAND
[2] KINGS COLL,SCH MED & DENT,LONDON SE5 9RS,ENGLAND
关键词
PROTEIN-S; PROTEIN-C; ANTITHROMBIN-III; HEPARIN COFACTOR-II; FULMINANT HEPATIC FAILURE;
D O I
10.1097/00001721-199206000-00002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To study the effect of the severe loss of hepatic synthetic function on the inhibitors of coagulation we have measured protein S (total and free), protein C, heparin cofactor II and antithrombin III in 30 patients with fulminant hepatic failure. The results showed severe reduction in all inhibitor levels with mean (+/- SE) values of: protein S, 0.26 +/- 0.03 U/ml; protein C, 0.26 +/- 0.03 U/ml; heparin cofactor II, 0.12 +/- 0.02 U/ml and antithrombin III, 0.21 +/- 0.02 U/ml. Heparin cofactor II was significantly lower than the other inhibitors (P < 0.01). Although the reduction in free protein S was significant in fulminant hepatic failure as compared to normal subjects (0.40 +/- 0.05 U/ml compared to 1.02 +/- 0.08 U/ml, P < 0.001), the ratio of free to total protein S was significantly increased (0.67 +/- 0.02 compared to 0.40 +/- 0.04, P < 0.01). Prothrombin time (INR) was significantly inversely correlated with total protein S (r = -0.56, P < 0.001) and free protein S (r = -0.48, P < 0.01), but not with the ratio of free to total protein S. No significant correlation between the different coagulation inhibitors and other measures of hepatic function could be detected. Although the loss of hepatic synthetic function appears to be the major cause of the loss of coagulation inhibitors, other effects such as increased consumption and rate of clearance may play a role. The balance of these will be reflected in the circulating levels of the coagulation inhibitors.
引用
收藏
页码:243 / 247
页数:5
相关论文
共 50 条
  • [41] FULMINANT HEPATIC-FAILURE IN CHILDHOOD
    不详
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1980, 281 (6244): : 823 - 824
  • [42] FULMINANT HEPATIC-FAILURE TREATED BY HEPATIC TRANSPLANTATION
    ADAMS, DH
    KIRBY, RM
    CLEMENTS, D
    ELIAS, E
    MCMASTER, P
    [J]. LANCET, 1986, 2 (8514): : 1037 - 1037
  • [43] HEPATIC REGENERATION - IMPLICATIONS IN FULMINANT HEPATIC-FAILURE
    TERBLANCHE, J
    STARZL, TE
    [J]. INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1979, 2 (02): : 49 - 52
  • [44] FULMINANT HEPATIC-FAILURE AND HEPATIC-ENCEPHALOPATHY
    ROGERS, EL
    ROGERS, MC
    [J]. PEDIATRIC CLINICS OF NORTH AMERICA, 1980, 27 (03) : 701 - 713
  • [45] COAGULATION-FACTOR CONCENTRATE IN TREATMENT OF HEMORRHAGIC DIATHESIS OF FULMINANT HEPATIC-FAILURE
    GAZZARD, BG
    LEWIS, ML
    ASH, G
    RIZZA, CR
    BIDWELL, E
    WILLIAMS, R
    [J]. GUT, 1974, 15 (12) : 993 - 998
  • [46] CONTINUOUS HEMOPERFUSION FOR FULMINANT HEPATIC-FAILURE
    INABA, S
    KISHIKAWA, T
    ZAITSU, A
    ISHIBASHI, H
    KUDO, J
    OGAWA, R
    YOSHIBA, M
    [J]. LANCET, 1991, 338 (8778): : 1342 - 1343
  • [47] HISTOPATHOLOGICAL HETEROGENEITY IN FULMINANT HEPATIC-FAILURE
    HANAU, C
    MUNOZ, SJ
    RUBIN, R
    [J]. HEPATOLOGY, 1995, 21 (02) : 345 - 351
  • [48] FULMINANT HEPATIC-FAILURE ASSOCIATED WITH METHYLDOPA
    PUPPALA, AR
    STEINHEBER, FU
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 1977, 68 (06): : 578 - 581
  • [49] MANAGEMENT OPTIONS IN FULMINANT HEPATIC-FAILURE
    KRAMER, DJ
    AGGARWAL, S
    MARTIN, M
    DARBY, J
    OBRIST, W
    ROSENBLOOM, A
    MURRAY, G
    LINDEN, P
    MIRO, A
    [J]. TRANSPLANTATION PROCEEDINGS, 1991, 23 (03) : 1895 - 1898
  • [50] FULMINANT HEPATIC-FAILURE - TO TRANSPLANT OR NOT TO TRANSPLANT
    DEKNEGT, RJ
    SCHALM, SW
    [J]. NETHERLANDS JOURNAL OF MEDICINE, 1991, 38 (3-4): : 131 - 141